Response to the letter regarding our article: "Excess adiposity and cancer: evaluating a preclinical-clinical obesity framework for risk stratification" [0.03%]
关于我刊论文的来信回复："过度肥胖与癌症：评估肥胖风险分层的临床前及临床肥胖框架"
Michael F Leitzmann,Michael J Stein,Hansjörg Baurecht et al.
Michael F Leitzmann et al.
Use of surrogate endpoints in health technology assessment and reimbursement of treatments for the management of chronic kidney disease [0.03%]
替代终点在慢性肾脏病管理技术评估和报销中的应用分析报告
Rod S Taylor,Hiddo J L Heerspink,Marc Buyse et al.
Rod S Taylor et al.
The judicious use of surrogate endpoints as substitutes for patient relevant target outcomes can substantially reduce the size and duration of clinical trials, thereby driving down research and development costs and driving faster patient a...
Provision of gender-affirming hormones for trans and gender-diverse adults: a systematic review of health and quality of life outcomes, values and preferences, and costs [0.03%]
性别肯定激素治疗成人跨性别及性别多样化人群的卫生和生活质量结果、价值观与偏好以及费用的系统评价
Erin E Cooney,Ping Teresa Yeh,Katrina S Kennedy et al.
Erin E Cooney et al.
Background: Many transgender and gender-diverse individuals take gender-affirming hormones, but the evidence for their impact on health and wellbeing has not been comprehensively synthesized. ...
Real-world effectiveness of initial antiviral regimens in children with chronic hepatitis B: an age-stratified cohort study [0.03%]
初治慢性乙肝患儿的抗病毒治疗方案的疗效分析：基于年龄分层的队列研究
Sisi Li,Meng Yang,Ling Ye et al.
Sisi Li et al.
Background: Interferons (IFN-α) and nucleos(t)ide analogues (NAs) are currently the primary treatment options for children with chronic hepatitis B (CHB), but the efficacy of different initial antiviral regimens in child...
Influence of changing patterns in lung cancer treatment and survival on the cost-effectiveness of CT screening: a modeling study [0.03%]
肺癌治疗模式变化对CT筛查成本效益的影响：基于模型的研究
Koen de Nijs,Kevin Ten Haaf,Dana Moldovanu et al.
Koen de Nijs et al.
Background: With the introduction of immune- and targeted therapies, lung cancer survival has lengthened, but per-patient costs of treatment have also increased. Both the clinical outcomes and costs of late stage disease ...
Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programme [0.03%]
法国同情用药计划中囊性纤维化患者体内两种CFTRⅠ类变异体的艾勒克斯卡福尔-特扎卡福尔-伊瓦卡福尔的现实数据
Pierre-Régis Burgel,Emmanuelle Girodon,Neeraj Sharma et al.
Pierre-Régis Burgel et al.
Background: The European Medicines Agency has recently expanded the label of elexacaftor-tezacaftor-ivacaftor (ETI) to all people with cystic fibrosis (pwCF) aged 2 years and older who have at least one non-Class I mutati...
The prevalence and role of human metapneumovirus in respiratory tract infections: a systematic review and meta-analysis of global data [0.03%]
人副流感病毒在呼吸道感染中的流行率和作用：全球数据的系统评价和meta分析
Pegah Khales,Mohammad Hossein Razizadeh,Saied Ghorbani et al.
Pegah Khales et al.
Background: Human metapneumovirus (hMPV) is a significant respiratory pathogen, yet its global prevalence and epidemiological patterns remain poorly characterized. This study presents the first comprehensive systematic re...
Two-year outcomes of quantitative flow ratio-based physiology-guided percutaneous coronary intervention in patients with low-risk acute coronary syndrome: a prespecified secondary analysis of FAVOR III China [0.03%]
基于定量血流分数的低危急性冠脉综合征患者生理功能导向经皮冠状动脉介入治疗两年结果：FAVOR III China研究的预设性探索分析
Song Ding,Zien Zhou,Zhiguo Zou et al.
Song Ding et al.
Background: The benefits of physiology-guided management in acute coronary syndrome (ACS) remain inconclusive due to limited evidence. In our FAVOR III China trial, a quantitative flow ratio (QFR)-based physiology-guided ...
Development and validation of a novel score to predict adverse outcomes in paediatric congenital mitral regurgitation (PRIMARY): a multicentre cohort study [0.03%]
儿童先天性二尖瓣反流不良预后的预测评分（PRIIMARY）的开发与验证：多中心队列研究
Han Zhang,Chunhu Gu,Jin Shentu et al.
Han Zhang et al.
Background: Paediatric patients who underwent surgery for mitral regurgitation (MR) have a high risk of recurrence or death; however, no prediction tool has been developed to risk-stratify this challenging subpopulation. ...